MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
Status:
Completed
Trial end date:
2018-05-15
Target enrollment:
Participant gender:
Summary
This study will look at the safety and tolerability of the new drug MLN9708 in combination
with the existing drugs panobinostat and dexamethasone among patients with relapsed or
refractory multiple myeloma. This study will also look at the response and clinical benefit
of the treatment and the progression-free survival and overall survival of study
participants.